Guided chemotherapy based on patient‐derived mini‐xenograft models improves survival of gallbladder carcinoma patients

• DOI: 10.1186/s40880-018-0318-8
• Publication Date: 2018-07-17T12:24:33Z
• Authors: Ming Zhan; Rui‐meng Yang; Hui Wang; Min He; Wei Chen; Sun‐wang Xu; Lin‐hua Yang; Qiang Liu; Man‐mei Long; Jian Wang
• Keywords: Gallbladder Cancer

Abstract Background Gallbladder carcinoma is highly aggressive and resistant to chemotherapy, with no consistent strategy guide first line chemotherapy. However, patient‐derived xenograft (PDX) model has been increasingly used as an effective for in preclinical study of chemosensitivity. Methods Mini‐PDX was established using freshly resected primary lesions from 12 patients gallbladder examine the sensitivity five most commonly chemotherapeutic agents, namely gemcitabine, oxaliplatin, 5‐fluorouracil, nanoparticle albumin‐bound (nab)‐paclitaxel, irinotecan. The results were selection agents adjunctive treatment after surgery. Kaplan–Meier method compare overall survival (OS) disease free (DFS) 45 who received conventional chemotherapy gemcitabine oxaliplatin. Results Cell viability assays based on mini‐PDX revealed significant heterogeneities drug responsiveness. analysis showed that PDX‐guided group had significantly longer median OS (18.6 months; 95% CI 15.9–21.3 months) than (13.9 11.7–16.2 ( P = 0.030; HR 3.18; 1.47–6.91). Patients also DFS (17.6 14.5–20.6 (12.0 9.7–14.4 0.014; 3.37; 1.67–6.79). Conclusion use regimens could improve outcome carcinoma.